DAGLA抗体;DAGLA Antibody—艾普蒂

+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    

  
  

•  

   

     Flow cytometric analysis of HL-60 cells using CCL4 mouse mAb (green) and negative control (red).    

  
  

The diacylglycerol lipase alpha (DAGLA) antibody is a research tool targeting DAGLA, an enzyme critical to the endocannabinoid system. DAGLA, a serine hydrolase, catalyzes the production of 2-arachidonoylglycerol (2-AG), a major endogenous cannabinoid neurotransmitter. Expressed predominantly in postsynaptic neurons of the central nervous system (CNS), DAGLA regulates synaptic plasticity, neurodevelopment, and retrograde signaling by modulating 2-AG levels. Dysregulation of DAGLA activity has been implicated in neurological disorders, including epilepsy, anxiety, and neurodegenerative diseases.

DAGLA antibodies are widely used in techniques like Western blotting, immunohistochemistry, and immunofluorescence to study protein expression, localization, and functional roles in cellular and animal models. Commercial DAGLA antibodies are typically raised in hosts like rabbits or mice, with specificity validated against recombinant proteins or knockout controls. Researchers prioritize antibodies with minimal cross-reactivity to the closely related isoform DAGLB.

These tools have advanced understanding of DAGLA's involvement in synaptic communication, metabolic pathways, and disease mechanisms. Recent studies also explore DAGLA's potential as a therapeutic target for pain management and neuropsychiatric conditions. However, challenges remain in ensuring antibody reliability across experimental conditions, emphasizing the need for rigorous validation in specific applications.